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Abstract 
Carboxypeptidase X-1 (CPX-1) is an atypical member of the carboxypeptidase (CP) family of 
proteins involved in a variety of physiological and pathological processes.  However, unlike most 
other family members CPX-1 lacks catalytic activity making its biological function unclear.  CPX-1 
contains a 160 amino acid discoidin domain (DSD) that serves as a binding domain in other 
proteins prompting us to investigate a putative functional role for this domain in CPX-1.  
Sequence alignment confirmed the overarching homology between the DSD of CPX-1 and other 
DSDs whilst more detailed analysis revealed conservation of the residues known to form the 
collagen-binding trench within the DSD of the discoidin domain receptors (DDRs) 1 and 2.  
Biochemical characterisation of transiently expressed human CPX-1 revealed that CPX-1 was 
secreted in an N-glycosylation-dependent manner as treatment with the N-glycosylation 
inhibitor tunicamycin inhibited secretion concomitant with a reduction in CPX-1 mobility on 
Western blot.  Using a collagen pull-down assay we found that secreted CPX-1 bound collagen 
and this appeared independent of N-glycosylation as treatment with PNGaseF did not affect 
binding.  Further analysis under non-reducing and reducing (+DTT) conditions revealed that CPX-
1 was secreted in both monomeric and dimeric forms and only the former bound collagen.  
Finally, mutation of a key residue situated within the putative collagen-binding trench within 
the DSD of CPX-1 (R192A) significantly reduced secretion and collagen-binding by 40% and 60%, 
respectively.  Collectively these results demonstrate that CPX-1 is a secreted collagen-binding 
glycoprotein and provide a foundation for future studies investigating the function of CPX-1. 
 
Keywords 
Carboxypeptidase, Discoidin Domain, Collagen 
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Introduction 
The Carboxypeptidase (CP) superfamily of enzymes typically performs a broad range of 
functions by removing C-terminal amino acids from proteins and peptides.  As such, they play 
key roles in processes including the biosynthesis of neuropeptides and peptide hormones as 
well as in the degradation of proteins within the digestive tract.  The M14 family of 
metallocarboxypeptidases is the largest family of CPs and most, but not all, are active as 
peptidases [1].  The carboxypeptidase E (CPE) subfamily consists of eight members, of which five 
are enzymatically active peptidases [2].  The three members that lack catalytic activity, CPX-1, 
CPX-2 and aortic carboxypeptidase-like protein/adipocyte enhancer binding protein 1 
(ACLP/AEBP1) form a discrete subset [2].  Their CP domains show the highest degree of 
homology within the family with each lacking one or more residues critical for enzymatic activity 
and/or substrate binding [2,3,4].  Furthermore, each contains an N-terminal signal peptide 
followed by a discoidin domain (DSD), a domain not present in the other family members [2].  
DSDs, which are also called factor 5/8 type C domains [5], are 150-160 amino acid domains 
present in a large number of proteins with a wide range of functions [6].  They typically serve as 
binding domains, binding to a diverse array of molecules including growth factors, 
phospholipids and lipids, galactose and collagen, and are implicated in a range of physiological 
and pathophysiological processes [6,7,8]. 
CPX-1 was first identified and characterised almost 20 years ago when it was shown to be a 
secreted protein subject to N-glycosylation [3].  Empirical evidence suggests it lacks catalytic 
activity [3] and this finding is consistent with sequence alignments which reveal substitution of 
two residues critical for substrate binding (R117 and Y248 in CPB are replaced by Val and His 
residues, V408 and H558, in CPX-1) [2,3].  Thus, the molecular role and biological function of 
CPX-1 are unclear.  One study has described a role for CPX-1 in osteoclastogenesis [9].  A 
proteomics based approach revealed that CPX-1 levels were transiently increased upon RANKL-
stimulated induction of differentiation of pre-osteoclasts with a subsequent decrease in CPX-1 
levels as the cells progressed to mature osteoclasts [9].  Additional investigations demonstrated 
that constitutive overexpression of CPX-1 inhibited the formation of multinucleated osteoclasts, 
but not the generation of mononuclear pre-osteoclasts, prompting the suggestion that tightly-
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coordinated expression of CPX-1 may be required for the progression of pre-osteoclasts to 
osteoclasts [9].  Whilst establishing a putative role for CPX-1 in the efficient differentiation of 
osteoclasts these investigations provided no insight into the underlying molecular mechanisms. 
At the molecular level CPX-1 is a modular protein containing a classic signal peptide, a DSD and 
a catalytically inactive CP domain [3] (see Fig 1A).   Given the absence of enzymatic activity and 
the recognised functional and biological importance of the DSDs in a range of other proteins 
[6,7,8] we reasoned that increased understanding of the putative role of the DSD in CPX-1 
would help direct future studies investigating the biological function of CPX-1.  To this end, we 
have employed a complementary range of computational, cellular and biochemical approaches 
that show that CPX-1 is a secreted, collagen-binding glycoprotein. 
 
Materials and methods 
Reagents and antibodies 
Unless otherwise stated, general reagents were obtained from Sigma-Aldrich (Castle Hill, NSW, 
Australia) and tissue culture reagents were from Invitrogen (Mount Waverley, Victoria, 
Australia).  CPX-1 antibody was from R&D Systems (Minneapolis, MN, USA).  β-tubulin antibody 
was from Sigma-Aldrich.  Secondary antibodies were from Rockland Immunochemicals 
(Limerick, PA, USA). 
 
In silico approaches 
NetNGlyc 1.0 was used to predict putative N-Glycosylation sites 
(http://www.cbs.dtu.dk/services/NetNGlyc/)[10,11].  CLUSTAL multiple sequence alignment 
was used to perform sequence alignments (www.drive5.com/muscle/)[12]. 
 
CPX-1 overexpression 
Overexpression of human CPX-1 was performed using a CPX-1 expression vector from 
GeneCopoeia (Rockville, MD, USA).  Transfection into Chinese hamster ovary (CHO) cells or 
Human embryonic kidney cells (HEK) cells was performed using Lipofectamine and PLUS 
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Reagents according to the manufacturer’s instructions (Invitrogen).  Endogenous CPX-1 was 
undetectable by Western blot in both cell lines (not shown). 
 
Site directed mutagenesis 
Site directed mutagenesis was performed to generate CPX-1R192A (R192 to Ala) using the 
QuikChange mutagenesis kit according to the manufacturer’s instructions (Invitrogen).  
Sequence confirmation of CPX-1R192A was performed using Sanger sequencing. 
 
In vitro pull-down assay 
Binding conditions were optimised in preliminary studies to reduce non-specific binding to IgG-
agarose beads (which were used throughout as a negative control).  Prior to use collagen-
agarose beads, featuring collagen III, (Sigma) were washed once with PBS and twice with pull-
down buffer (150mM NaCl, 0.1% Triton X-100) and resuspended to give a 1:1 slurry of 
bead:buffer by volume.  CPX-1 in conditioned, serum free medium was prepared for use by 
concentrating (1 in 10-20) using Amicon Ultra Centrifugal Filters (30kDa) according to the 
manufacturer’s instructions (Millipore, Victoria, Australia).  This (5-10µl) was then incubated 
with collagen-agarose beads (30-50 µl) in pull-down buffer (total volume of 500µl) overnight at 
4°C or for 3h at 37°C with constant mixing.  Samples were centrifuged at 3,000 rpm for 30s and 
supernatant (unbound fraction) was transferred to a new tube and pellet (bound fraction) was 
washed 4 times with pull-down buffer.  Fractions were analysed by Western blot. 
 
Western blotting 
Western blotting was carried out using SDS-PAGE as described [13]. 
 
Statistical analyses 
Data are presented as mean ± SEM.  Significance was determined using students t-test with 
statistical significance defined as p < 0.05. 
3. Results 
CPX-1 is secreted in an N-glycosylation dependent manner 
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CPX-1 has been reported to be secreted in an N-glycosylated form [3].  In silico analysis revealed 
4 putative N-glycosylation sites in human CPX-1 including one situated within the DSD (Fig 1A).  
We reasoned that elucidation of the characteristics of N-glycosylation would increase our 
understanding of CPX-1 at the molecular level.  As N-glycosylation has been shown to be 
essential for efficient secretion of some but not all N-glycosylated proteins [14] we first 
determined whether N-glycosylation was required for efficient secretion of CPX-1.  Human CPX-
1 was transiently expressed in CHO cells and intracellular and secreted CPX-1 was analysed by 
Western blot.  The predicted molecular weight of CPX-1 (based on amino acid sequence) is 
80kDa.  Intracellular CPX-1 migrated at 80 and 100kDa whilst secreted CPX-1, present in 
conditioned medium, migrated predominantly at 120kDa, respectively (Fig 1B).  These 
observations are consistent with CPX-1 undergoing a series of post-translational modifications 
(PTMs) during transit through the secretory pathway. 
We used tunicamycin, an inhibitor of the enzyme N-acetylglucosamine phosphotransferase 
which catalyses the first step of N-glycosylation, to investigate a putative role for N-
glycosylation in the secretion of CPX-1.  Incubation of CPX-1 expressing cells with tunicamycin 
for 3h or 24h selectively reduced the intensity of the 100kDa band, with only the 80kDa form of 
intracellular CPX-1 detected after 24h (Fig 1C).  Moreover, 24h incubation with tunicamycin 
completely abolished secretion of CPX-1 (Fig 1D).   We used PNGaseF, which cleaves N-linked 
oligosaccharides, to complement and extend these observations.  Treatment of cell lysates with 
PNGaseF resulted in conversion of the intracellular 100kDa band to 80kDa (Fig 1E).  
Interestingly, treatment of conditioned media with PNGaseF resulted in conversion of the 
120kDa band to a band that migrated at around 100kDa but not 80kDa (Fig 1F).  Collectively 
these results demonstrate that N-glycosylation of CPX-1 is essential for efficient secretion and 
also raise the possibility that secreted CPX-1 may be subject to additional, PNGaseF-
independent PTM. 
 
In silico analysis suggests the DSD of CPX-1 may bind collagen  
In other proteins the DSD typically serves as a binding domain, where its biological role is 
determined predominantly by the nature of the binding partner [6].  Given the CP domain of 
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CPX-1 is catalytically inactive [3] characterisation of the DSD may be expected to provide useful 
insights into the putative function of CPX-1.  To address this we performed an alignment of the 
DSDs from several proteins including the other two CPE subfamily members that lack catalytic 
activity, namely CPX-2 and ACLP, the collagen-binding DDRs, DDR1 & DDR2, the phospholipid-
binding Coagulation Factors V and VIII, and the semaphorin receptor Neuropilin-1 (Fig 2).  There 
was relatively modest homology at the primary sequence level with 20 identical and 32 
conserved residues, consistent with previous analyses [6].  As expected the greatest homology 
with CPX-1 was observed for CPX-2 and ACLP, sharing 58.9 and 53.2% identity.  The other DSDs 
shared between 35-29% identity with the CPX-1 DSD showing greatest homology with the DSDs 
of the collagen-binding DDRs (Fig 2).  The molecular details of the DSD–collagen interaction 
have been elucidated through a combination of NMR studies [15], resolution of the crystal 
structure of the DDR2-DSD–collagen complex [16], and functional investigations exploring the 
collagen-binding site within the DDR1-DSD [17].  Together, these studies indicate that the four 
surface-exposed loops situated within the DSD combine to form an amphiphilic binding trench 
that binds to the GVMGFO motifs present in fibrillar collagens I-III [15,16,17].  Key residues that 
define this binding trench include the apolar residues W52, T56 & C73-C177 (Q136, L140 & 
C164-C266 in CPX-1) as well as the charged residues D69, R105 & E113 (D160, R192 & D199 in 
CPX-1) [16](Fig 2).  Our sequence alignment revealed these key residues were highly conserved 
in CPX-1, and CPX-2 and ACLP.  Furthermore, ACLP has been reported to associate with collagen 
I [18].   These observations prompted us to hypothesise that the CPX-1 DSD may serve as a 
collagen-binding domain. 
 
CPX-1 binds collagen  
To determine whether CPX-1 bound collagen we used an in vitro “pull-down” assay featuring 
agarose beads conjugated with either collagen III or IgG (control) and secreted CPX-1, 
concentrated from conditioned culture medium.  CPX-1 was pulled down by the collagen but 
not the IgG control beads demonstrating that CPX-1 is able to bind collagen (Fig 3A – compare 
lanes 2 & 4 with lanes 3 & 5).  Quantitation across multiple experiments revealed 15-20% of the 
recombinant CPX-1 bound under the assay conditions used.   
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N-glycosylation is not required for collagen binding 
Having demonstrated that N-glycosylation of CPX-1 was essential for secretion we investigated 
whether N-glycosylation was required for collagen binding.  To examine this we pre-treated 
secreted CPX-1 with PNGaseF prior to performing the pull-down assay.  PNGaseF-treated CPX-1 
bound collagen with similar efficacy to untreated CPX-1 (Fig 3B - compare lanes 2 & 5).  These 
results suggest that N-glycosylation is not required for collagen binding although it is a 
prerequisite for CPX-1 secretion. 
 
CPX-1 exists as monomer and dimer - only monomer binds collagen  
DSDs are often found in pairs with some proteins containing a pair of DSDs, including the 
Coagulation Factors V and VIII and Neuropilin 1, whilst others contain a single DSD but form 
dimers, such as the DDRs.  In the latter case dimerisation may be mediated by disulphide bonds, 
situated external to the DSD, and or interactions between the transmembrane domains and 
dimerisation appears to be critical for ligand binding and biological function [19,20].  To 
investigate whether CPX-1 may form disulphide-mediated dimers and, if so, whether 
dimerisation affected collagen binding we analysed secreted CPX-1 both pre and post collagen 
pull-down under non-reducing (-DTT) and standard reducing (+DTT) conditions.  Analysis under 
non-reducing conditions demonstrated the presence of two major secreted CPX-1 species that 
migrated with mobility consistent with monomer and dimer (Fig 3C – lane 1).  Quantitation of 
the proportion of monomer to dimer from 3 independent experiments indicated a ratio of 3 to 
2.  Perhaps surprisingly, only the CPX-1 monomer bound collagen (Fig 3C – compare lane 2 with 
lanes 1 & 3).  These results demonstrate that CPX-1 is capable of forming disulphide-mediated 
dimers but only monomeric CPX-1 is able to bind collagen, suggesting dimerisation precludes 
collagen binding. 
 
The DSD is required for CPX-1 binding to collagen 
Finally, to investigate the putative role of the DSD in the CPX-1 – collagen binding interaction we 
generated and characterised a mutant form of CPX-1, termed CPX-1R192A, where the conserved 
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R192 residue situated within the third loop of the DSD (see Fig 2) and integral to the binding 
trench [16] was mutated to Ala.  A previous report showed that mutation of the equivalent 
residue in DDR1 (R105) reduced collagen binding by 80%  [17].  We compared the expression, 
secretion and binding characteristics of CPX-1R192A and wild-type (WT) CPX-1.  The intracellular 
levels of CPX-1R192A were comparable to those of the WT protein (Fig 4A).  Secretion of CPX-
1R192A was compromised by 40% relative to WT (Fig 4B).  Furthermore, compared with WT, 
collagen binding of CPX-1R192A was reduced by 60% (Fig 4C).  These results indicate that an intact 
DSD is required for efficient binding of CPX-1 to collagen and suggest that even conservative 
mutations within the DSD may compromise CPX-1 folding and secretion. 
 
Discussion 
Determining the cellular, molecular and biological characteristics and functions of proteins of 
unknown function represents a challenge that can be addressed using computational and 
biochemical methods [21].  In the current study we have employed such complementary 
approaches to show that CPX-1 is a secreted collagen-binding glycoprotein.  We have shown 
that secretion of CPX-1 is dependent on N-glycosylation and that CPX-1 is secreted in both 
monomeric and dimeric forms.  N-glycosylation of CPX-1 does not appear to be essential for 
collagen binding whilst only the monomer binds collagen.  We also report that mutation of a key 
residue within the CPX-1 DSD (R192) reduced collagen binding providing direct evidence of a 
role for the DSD in this interaction.  These observations provide a framework for future 
investigations exploring the biological function of CPX-1. 
CPX-1 was identified as a novel member of the CPE subfamily that lacked catalytic activity [3].  
Preliminary characterisation indicated that CPX-1 was a secreted glycoprotein that exhibited a 
relatively restricted expression profile prompting speculation that CPX-1 may be involved in 
developmental processes [3].  A subsequent report implicated CPX-1 in the process of 
osteoclastogenesis [9].  In the current report we first confirmed that CPX-1 is a secreted 
glycoprotein and then extended these observations demonstrating that efficient secretion of 
CPX-1 is dependent on N-glycosylation.   This finding suggests that N-glycosylation of CPX-1 
facilitates its appropriate folding and enables it to attain a secretion-competent conformation.  
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In silico analysis revealed 4 putative N-glycosylation sites.  Notably, PNGaseF treatment of 
secreted CPX-1 did not restore CPX-1 to its ‘ground state’ of 80kDa, as was observed for 
intracellular CPX-1.  One possibility is that secreted CPX-1 may comprise additional PNGaseF-
insensitive PTMs.  These may reflect fucose-linked α(1→3) N-glycans, which are resistant to the 
action of PNGaseF, or discrete PTMs.  Another possibility is that secreted CPX-1 may be folded 
such that steric hindrance may preclude PNGaseF access to all N-glycan moieties.  Additional 
studies are required to elaborate these details.   
A focus of the current report was to establish a putative molecular role for CPX-1 by focusing on 
the DSD.  Sequence alignment demonstrated conservation of around 50% with DSDs in related 
proteins, CPX-2 and ACLP, and around 30% with DSDs from non-related proteins, with the 
highest identity shared with the collagen-binding DSDs from the DDRs.  More detailed analysis 
revealed conservation of key residues involved in mediating the DDR-DSD – collagen interaction 
via the formation of an amphiphilic binding trench [16,17].  These residues are also conserved in 
CPX-2 and ACLP, with the latter reported to associate with collagen I in studies implicating ACLP 
in pulmonary fibrosis [18].  This high degree of conservation prompted us to speculate that the 
CPX-1 DSD may serve as a collagen binding domain.  Our in vitro binding studies, using collagen 
III, demonstrated that CPX-1 is able to bind collagen.  
Further investigations indicated that removal of the PNGaseF-sensitive N-glycan(s) did not affect 
such binding.  One of the putative N-glycosylation sites (N210) is situated within the DSD, 
between loops 3 and 4, at a site that is conserved in CPX-2 and ACLP.  A putative N-glycosylation 
site is similarly located within the DSD of DDR2.  However, detailed characterisation of DDR2 
indicates this site is not glycosylated [5] and our modelling studies (not shown) suggest these 
residues are distinct from the binding trench.   In contrast, a phospholipid-binding DSD within 
Factor VIII contains a validated N-glycosylation site [22] that, in combination with other N-
glycans, facilitates binding [23].  Moreover, N-glycosylation of DDR1 at a residue distal to the 
DSD (N211), that is conserved in DDR2, has been shown to affect receptor activation [24].  
Collectively these observations support the notion that glycosylation is unlikely to directly affect 
the DSD – collagen interaction per se but is likely to be important for modulation of 
conformation in the absence and or presence of collagen [5,24]. 
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Dimerisation of the DDRs has consistently been reported to be essential for efficient collagen 
binding [19,20,25].  Studies of the extracellular domains of both DDR1 and DDR2 indicated that 
collagen binding required dimerisation [19,20] with transmembrane-interactions [25] and 
disulphide-bonds [19] proposed as key mediators of dimerisation.  In the current report we 
showed that CPX-1 is secreted in both monomeric and dimeric form with the dimer being 
sensitive to reduction with DTT consistent with disulphide-mediated dimerisation.   The DSD 
contains four conserved cysteines that, based on the DDR-DSDs [5], are likely to form two 
intramolecular disulphide bonds, one that links the N- and C-termini of the DSD (C115 & C274) 
and one that forms a disulphide bridge at the bottom of the collagen-binding trench (C164 & 
C266).  There are seven additional cysteines present in CPX-1 and it seems likely that one or 
more of these are involved in the formation of disulphide-linked dimers.  Notwithstanding, our 
results suggest that monomeric, but not dimeric, CPX-1 binds collagen.  Whilst this contrasts 
with the scenario described above for the DDRs it is supported by observations, albeit indirect, 
where a recombinant monomeric form of the DSD from ACLP was shown to be sufficient to 
restore collagen-dependent function in ACLP
-/-
 lung fibroblasts [18]. 
It is tempting to speculate that, like the DDRs, CPX-1, as well as CPX-2 and ACLP, binds to the 
GVMGFO motif common to the fibrillar collagens I-III [15,16,17].  Detailed investigations have 
established relative specificity with respect to DDR-binding to alternate, non-fibrillar collagens 
such as the collagens IV and X and have also revealed that such specificity is defined by non-
conserved residues located at the periphery of the binding trench [26].   Such investigations 
provide a framework by which to elaborate the detailed collagen-binding properties of CPX-1, 
CPX-2 and ACLP.  The molecular role of these proteins is, as with other DSD-containing proteins, 
likely to be determined by the nature of the DSD-binding partners.  Although relatively little is 
known about CPX-1 or CPX-2, ACLP typically exhibits high levels of expression in collagen-rich 
tissues and emerging evidence suggests a collagen-associated role for ACLP in physiological and 
pathophysiological processes such as adipogenesis and pulmonary fibrosis [18,27], thereby 
highlighting novel potential therapeutic opportunities afforded by such understanding. 
In summary, we have shown that CPX-1 is a secreted collagen-binding glycoprotein and, based 
on this and previous observations, we propose that the molecular function of the three 
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secreted, catalytically-inactive CPE subfamily of proteins, namely CPX-1, CPX-2 and ACLP, is 
likely to be elaborated, at least in part, by defining the molecular details of the respective DSD-
collagen interaction. 
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Figure Legends 
Figure 1 – N-glycosylation of CPX-1 is required for secretion. (A) Schematic showing 
organisation of CPX-1 and location of putative N-glycosylation sites (stars) at residues 57, 210, 
318 and 472.  (B) CPX-1 was transiently expressed in CHO cells and intracellular (lysate) and 
secreted (media) CPX-1 was analysed by Western blot.  (C & D) CPX-1 expressing CHO cells were 
treated with tunicamycin (Tuni - 10 μg/ml) for 24h or 3h and intracellular and secreted CPX-1 
was analysed by Western blot.  (E & F) Intracellular and secreted CPX-1 were treated with 
PNGaseF (2.5 units for 2h) and analysed by Western blot.  Blots are representative of 3 
independent experiments. 
 
Figure 2 – In silico analysis of the DSD within CPX-1.  Multiple sequence alignment of the DSD 
in human CPX-1, CPX-2, ACLP, DDR1, DDR2, Factor V, Neuropilin I and Factor VIII in decreasing 
order of homology.  Loop regions (1-4) are boxed in grey.  Conserved residues that form the 
collagen-binding trench are boxed in yellow.  Putative N-glycosylation sites are underlined in 
green.  The degree of conservation across all 8 DSDs is denoted as (*) identical, (:) highly 
conserved and (.) conserved; Additional conservation across CPX-1/2, ACLP & DDR1/2 is 
denoted as (*, : and .) respectively.  Numbers in parentheses depict % identity with CPX-1. 
 
Figure 3 – CPX-1 binds collagen. (A)  Secreted CPX-1 was incubated with collagen-agarose beads 
(col), or IgG-agarose beads (IgG) as control, and bound (B) and unbound (UB) material was 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
analysed by Western blot.  ST – starting material.  (B) As in (A) except samples were pre-treated 
with PNGaseF as indicated prior to incubation with the collagen-agarose beads.  (C) As in (A) 
except following incubation with the collagen-agarose beads both bound and unbound samples 
were treated -/+ DTT prior to Western blot.  Blots are representative of 3 independent 
experiments. 
 
Figure 4 – Mutation of the CPX-1 DSD compromises collagen binding. (A & B) Wild-type CPX-1 
(WT) and CPX-1R192A (R192A) were transiently expressed in HEK cells and intracellular (cell 
lysates - A) and secreted (conditioned media - B) CPX-1 was analysed by Western blot.  (C) 
Secreted WT and mutant CPX-1 were incubated with collagen agarose beads and bound (B) and 
unbound (UB) material was analysed by Western blot.  Graphs show quantitation from 6 
independent experiments. *p<0.05 WT cf R192A. 
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Figure 1 - Single column
A
B C
Carboxypeptidase
domain
Discoidin
domain
Signal
peptide
1 20 116 273 295 620 734
80
100
120
CPX-1
-
80
100CPX-1
β-tubulin
CPX-1
Tuni -
+ + +
- 24h 3h
FD E
Tuni -
CPX-1
100
120
CPX-1
β-tubulin
80
100
PNGase - +
100
120
CPX-1
PNGase - ++
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure 2 - Double column
                 115                   Loop 1                Loop 2                   
CPX-1            CP-PLGLESLRVSDSRLEASSSQSFGLGPHRGRLNIQSGLEDGDLYDGAWCAE----EQD 
CPX-2            CP-PLGLETLKITDFQLHASTVKRYGLGAHRGRLNIQAGINENDFYDGAWCAG----RND 
ACLP             CP-PIGMESHRIEDNQIRASSMLRHGLGAQRGRLNMQTGATEDDYYDGAWCAE----DDA 
DDR2             CRYPLGMSGGQIPDEDITASSQWSESTAAKYGRLDSEEG-------DGAWCPEIPVEPDD 
DDR1             CRYALGMQDRTIPDSDISASSSWSDSTAARHSRLESSDG-------DGAWCPAGSVFPKE 
Factor V(1)      CRMPMGLSTGIISDSQIKASEFLGY-WEPRLARLNNGGS-------YNAWSVEKLAAEFA 
Neuropilin 1(1)  CMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYP---------ENGWTPG----EDS 
Factor VIII(1)   CQTPLGMASGHIRDFQITASGQYGQ-WAPKLARLHYSGS-------INAWS------TKE 
                 *  .:*:    : *  : **:    . ... .**: . *       *****.      . 
 
                 170                     Loop 3 
CPX-1            ADPWFQVDAGHPTRFSGVITQGRNSVWRY-D-WVTSYKVQFSNDSRTWWGSRNHSSGMDA 
CPX-2            LQQWIEVDARRLTRFTGVITQGRNSLWLS-D-WVTSYKVMVSNDSHTWVTVKNGSGDM-- 
ACLP             RTQWIEVDTRRTTRFTGVITQGRDSSIHD-D-FVTTFFVGFSNDSQTWVMYTNGYEEM-- 
DDR2             LKEFLQIDLHTLHFITLVGTQGRHAGGHGIE-FAPMYKINYSRDGTRWISWRNRHGKQ-- 
DDR1             -EEYLQVDLQRLHLVALVGTQGRHAGGLGKE-FSRSYRLRYSRDGRRWMGWKDRWGQE-- 
Factor V(1)      SKPWIQVDMQKEVIITGIQTQGAKHYLKSC--YTTEFYVAYSSNQINWQIFKGNSTRNVM 
Neuropilin 1(1)  YREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPV-- 
Factor VIII(1)   PFSWIKVDLLAPMIIHGIKTQGARQKFSSL--YISQFIIMYSLDGKKWQTYRGNSTGTLM 
                    ::::*      .: : ****       : :   : :  *.:.  *    .        
 
                 230                          Loop 4           274  (% identity) 
CPX-1            VFPANSDPETPVLNLLPEPQVARFIRLLPQTWLQGGAPCLRAEILAC     (100.0) 
CPX-2            IFEGNSEKEIPVLNELPVPMVARYIRINPQSWFDNGSICMRMEILGC      (58.9) 
ACLP             TFHGNVDKDTPVLSELPEPVVARFIRIYPLTW--NGSLCMRLEVLGC      (53.2) 
DDR2             VLDGNSNPYDIFLKDLEPPIVARFVRFIPVTD-HSMNVCMRVELYGC      (34.7) 
DDR1             VISGNEDPEGVVLKDLGPPMVARLVHFYPRAD-RVMSVCLRVELYGC      (34.2) 
Factor V(1)      YFNGNSDASTIKENQFDPPIVARYIRISPTRA--YNRPTLRLELQGC      (32.7) 
Neuropilin 1(1)  LFQGNTNPTDVVVAVFPKPLITRFVRIKPATW--ETGISMRFEVYGC      (30.6) 
Factor VIII(1)   VFFGNVDSSGIKHNIFNPPIIARYIRLHPTHY--SIRSTLRMELMGC      (29.1) 
                  : .* :    .*. :  * ::* :.: * :       *:* *: .* 
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Figure 3 - Single column
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Figure 4 - Single column
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Highlights 
 
 
• The discoidin domain-containing protein CPX-1 is secreted 
o in an N-glycosylation dependent manner 
o in monomeric and dimeric forms 
• CPX-1 binds collagen 
o in an N-glycosylation independent manner 
o in monomeric form only 
• Mutation of the discoidin domain compromises collagen binding 
 
 
